SP
VRTX icon

SWS Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

SWS Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Buy
2,573
+42
+2% +$19.6K 0.28% 86
2025
Q4 		$1.15M Buy
2,531
+13
+0.5% +$5.6K 0.28% 90
2025
Q3 		$986K Buy
2,518
+36
+1% +$15K 0.24% 96
2025
Q2 		$1.11M Buy
+2,482
New +$1.14M 0.3% 92
2025
Q1 		– Sell
-3,267
Closed -$1.32M – 117
2024
Q4 		$1.32M Buy
3,267
+20
+0.6% +$9.27K 0.4% 85
2024
Q3 		$1.51M Sell
3,247
-362
-10% -$174K 0.48% 76
2024
Q2 		$1.69M Sell
3,609
-737
-17% -$320K 0.51% 74
2024
Q1 		$1.82M Sell
4,346
-56
-1% -$23.7K 0.54% 73
2023
Q4 		$1.79M Sell
4,402
-72
-2% -$26.6K 0.58% 69
2023
Q3 		$1.56M Sell
4,474
-1,114
-20% -$390K 0.58% 70
2023
Q2 		$1.96M Sell
5,588
-60
-1% -$20.2K 0.71% 63
2023
Q1 		$1.78M Buy
+5,648
New +$1.69M 0.66% 69
2022
Q4 		– Sell
-5,592
Closed -$1.62M – 105
2022
Q3 		$1.62M Buy
5,592
+28
+0.5% +$8.06K 0.75% 60
2022
Q2 		$1.57M Buy
5,564
+11
+0.2% +$2.94K 1.32% 43
2022
Q1 		$1.45M Sell
5,553
-4,304
-44% -$1.02M 0.95% 58
2021
Q4 		$2.17M Buy
9,857
+2,508
+34% +$488K 1.23% 35
2021
Q3 		$1.33M Buy
7,349
+135
+2% +$26.4K 0.83% 64
2021
Q2 		$1.46M Buy
7,214
+140
+2% +$29.3K 0.95% 55
2021
Q1 		$1.52M Buy
7,074
+3,289
+87% +$722K 1.05% 48
2020
Q4 		$895K Buy
3,785
+1,030
+37% +$236K 0.4% 90
2020
Q3 		$750K Buy
2,755
+299
+12% +$82.5K 0.38% 79
2020
Q2 		$668K Buy
2,456
+261
+12% +$70.8K 0.85% 51
2020
Q1 		$522K Buy
+2,195
New +$504K 0.37% 75
2019
Q3 		$337K Sell
1,613
-178
-10% -$31.5K 0.2% 92
2019
Q2 		$319K Buy
+1,791
New +$313K 0.2% 94
2018
Q4 		$233K Sell
1,407
-132
-9% -$22.9K 0.18% 95
2018
Q3 		$297K Buy
+1,539
New +$274K 0.19% 86

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

SWS Partners's VRTX Position: Q1 2026 in Review

SWS Partners increased its Vertex Pharmaceuticals (VRTX) stake by 1.7% in Q1 2026, buying an estimated $19.6K and bringing the position to 2,573 shares worth $1.15M. The position accounts for 0.28% of the portfolio, ranked #86.

SWS Partners first reported a position in VRTX in Q3 2018 and has held it in 27 quarters since. The position peaked at $2.17M in Q4 2021. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • SWS Partners held 2,573 shares of Vertex Pharmaceuticals worth $1.15M as of Q1 2026.
  • SWS Partners bought 42 Vertex Pharmaceuticals shares in Q1 2026, an estimated $19.6K.
  • Vertex Pharmaceuticals made up 0.28% of SWS Partners's portfolio in Q1 2026, its #86 holding.
  • SWS Partners first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 27 quarters since.
  • SWS Partners's Vertex Pharmaceuticals position peaked at $2.17M in Q4 2021.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on SWS Partners's 13F filing for Q1 2026, filed 21 Apr 2026.